| Title |
Prognostic and Predictive Factors for Renal Cell Carcinoma
|
|---|---|
| Published in |
Targeted Oncology, March 2018
|
| DOI | 10.1007/s11523-018-0557-2 |
| Pubmed ID | |
| Authors |
Cristina Suárez, Marc Campayo, Romà Bastús, Sergi Castillo, Olatz Etxanitz, Marta Guix, Núria Sala, Enrique Gallardo |
| Abstract |
Metastatic renal cell carcinoma (mRCC) is an incurable malignancy, characterized by its resistance to traditional chemotherapy, radiation, and hormonal therapy. Treatment perspectives and prognosis of patients with mRCC have been significantly improved by advances in the understanding of its molecular pathogenesis, which have led to the development of targeted therapeutics. Different molecular factors derived from the tumor or the host detected in both tissue or serum could be predictive of therapeutic benefit. Some of them suggest a rational selection of patients to be treated with certain therapies, though none have been validated for routine use. This article provides an overview of both clinical and molecular factors associated with predictive or prognostic value in mRCC and emphasizes that both should be considered in parallel to provide the most appropriate, individualized treatment and achieve the best outcomes in clinical practice. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 24% |
| Student > Master | 2 | 12% |
| Student > Postgraduate | 2 | 12% |
| Researcher | 2 | 12% |
| Other | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 6 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 47% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Veterinary Science and Veterinary Medicine | 1 | 6% |
| Unknown | 7 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2018.
All research outputs
#15,498,204
of 23,031,582 outputs
Outputs from Targeted Oncology
#270
of 555 outputs
Outputs of similar age
#212,284
of 332,503 outputs
Outputs of similar age from Targeted Oncology
#13
of 17 outputs
Altmetric has tracked 23,031,582 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 555 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.